ABEONA THERAPEUTICS INC. Operating Expenses
ABEONA THERAPEUTICS INC. (ABEO) reported Operating Expenses of $23.19 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-08-14
- ABEONA THERAPEUTICS INC. operating expenses for the quarter ending 2025-06-30 was $23.19M, a 29.83% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating expenses for the quarter ending 2025-03-31 was $19.73M, a 37.66% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating expenses for the quarter ending 2024-12-31 was $16.67M, a 26.22% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating expenses for the quarter ending 2024-09-30 was $15.35M, a 35.39% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating expenses for fiscal 2024 was $64.21M, a 26.81% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. operating expenses for fiscal 2023 was $50.63M, a 3.24% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. operating expenses for fiscal 2022 was $52.33M, a 43.63% decline from fiscal 2021.
- ABEONA THERAPEUTICS INC. operating expenses for fiscal 2021 was $92.84M, a 1.55% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2025-06-30 | $23.19M 10-Q · filed 2025-08-14 | $42.92M 10-Q · filed 2025-08-14 | $59.59M derived: sum of 3 quarters · filed 2025-08-14 | $74.94M derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $19.73M 10-Q · filed 2025-05-15 | $36.40M derived: sum of 2 quarters · filed 2025-05-15 | $51.74M derived: sum of 3 quarters · filed 2025-05-15 | $69.61M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-12-31 | $16.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $32.02M derived: sum of 2 quarters · filed 2025-03-20 | $49.88M derived: sum of 3 quarters · filed 2025-08-14 | $64.21M 10-K · filed 2025-03-20 |
| 2024-09-30 | $15.35M 10-Q · filed 2024-11-14 | $33.21M derived: sum of 2 quarters · filed 2025-08-14 | $47.54M 10-Q · filed 2024-11-14 | $60.75M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $17.86M 10-Q · filed 2025-08-14 | $32.19M 10-Q · filed 2025-08-14 | $45.40M derived: sum of 3 quarters · filed 2025-08-14 | $56.74M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $14.33M 10-Q · filed 2025-05-15 | $27.54M derived: sum of 2 quarters · filed 2025-05-15 | $38.87M derived: sum of 3 quarters · filed 2025-05-15 | $52.93M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $24.54M derived: sum of 2 quarters · filed 2025-03-20 | $38.60M derived: sum of 3 quarters · filed 2025-03-20 | $50.63M 10-K · filed 2025-03-20 |
| 2023-09-30 | $11.33M 10-Q · filed 2024-11-14 | $25.39M derived: sum of 2 quarters · filed 2024-11-14 | $37.43M 10-Q · filed 2024-11-14 | $50.43M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $14.05M 10-Q · filed 2024-08-12 | $26.09M 10-Q · filed 2024-08-12 | $39.10M derived: sum of 3 quarters · filed 2024-08-12 | $48.48M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $12.04M 10-Q · filed 2024-05-15 | $25.04M derived: sum of 2 quarters · filed 2024-05-15 | $34.42M derived: sum of 3 quarters · filed 2024-05-15 | $43.43M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $22.38M derived: sum of 2 quarters · filed 2024-03-18 | $31.39M derived: sum of 3 quarters · filed 2024-03-18 | $52.33M 10-K · filed 2024-03-18 |
| 2022-09-30 | $9.38M 10-Q · filed 2023-11-13 | $18.39M derived: sum of 2 quarters · filed 2023-11-13 | $39.33M 10-Q · filed 2023-11-13 | $88.98M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $9.01M 10-Q · filed 2023-08-08 | $29.95M 10-Q · filed 2023-08-08 | $79.60M derived: sum of 3 quarters · filed 2023-08-08 | $94.47M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $20.94M 10-Q · filed 2023-05-11 | $70.59M derived: sum of 2 quarters · filed 2023-05-11 | $85.46M derived: sum of 3 quarters · filed 2023-05-11 | $99.18M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $49.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $64.52M derived: sum of 2 quarters · filed 2023-03-29 | $78.24M derived: sum of 3 quarters · filed 2023-03-29 | $92.84M 10-K · filed 2023-03-29 |
| 2021-09-30 | $14.87M 10-Q · filed 2022-11-14 | $28.59M derived: sum of 2 quarters · filed 2022-11-14 | $43.18M 10-Q · filed 2022-11-14 | $60.66M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $13.71M 10-Q · filed 2022-08-11 | $28.31M 10-Q · filed 2022-08-11 | $45.79M derived: sum of 3 quarters · filed 2022-08-11 | $59.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $14.60M 10-Q · filed 2022-05-13 | $32.08M derived: sum of 2 quarters · filed 2022-05-13 | $45.33M derived: sum of 3 quarters · filed 2022-05-13 | $57.81M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $30.73M derived: sum of 2 quarters · filed 2022-03-31 | $43.21M derived: sum of 3 quarters · filed 2022-03-31 | $91.42M 10-K · filed 2022-03-31 |
| 2020-09-30 | $13.25M 10-Q · filed 2021-11-15 | $25.73M derived: sum of 2 quarters · filed 2021-11-15 | $73.94M 10-Q · filed 2021-11-15 | $90.35M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $12.48M 10-Q · filed 2021-07-28 | $60.69M 10-Q · filed 2021-07-28 | $77.10M derived: sum of 3 quarters · filed 2021-07-28 | $94.75M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $48.21M 10-Q · filed 2021-05-17 | $64.62M derived: sum of 2 quarters · filed 2021-05-17 | $82.27M derived: sum of 3 quarters · filed 2021-05-17 | $106.25M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $16.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $34.06M derived: sum of 2 quarters · filed 2021-03-24 | $58.04M derived: sum of 3 quarters · filed 2021-03-24 | $77.09M 10-K · filed 2021-03-24 |
| 2019-09-30 | $17.65M 10-Q · filed 2020-11-09 | $41.63M derived: sum of 2 quarters · filed 2020-11-09 | $60.68M 10-Q · filed 2020-11-09 | $79.17M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $23.98M 10-Q · filed 2020-08-10 | $43.03M 10-Q · filed 2020-08-10 | $61.52M derived: sum of 3 quarters · filed 2020-08-10 | $80.15M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $19.05M 10-Q · filed 2020-05-06 | $37.55M derived: sum of 2 quarters · filed 2020-05-06 | $56.17M derived: sum of 3 quarters · filed 2020-05-06 | |
| 2018-12-31 | $18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $37.12M derived: sum of 2 quarters · filed 2020-03-16 | $61.16M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $18.63M 10-Q · filed 2019-11-12 | $42.67M 10-Q · filed 2019-11-12 | ||
| 2017-12-31 | $28.67M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |